Biopsy and Resection Growth Patterns in Colorectal Peritoneal Cancer
Official title: Biopsy-Resection Agreement of Peritoneal Histopathological Growth Patterns in Colorectal Peritoneal Metastases: A Prospective Observational Pilot Study
Run by Jules Bordet Institute · NCT07474025 · Data updated 2026-11-12
This study tests whether peritoneal growth patterns seen on small biopsies during staging laparoscopy match the patterns found in later surgical specimens for adults with colorectal peritoneal metastases.
Quick facts
| Study type | Observational |
|---|---|
| Ages | Any age to 100 Years |
| Sex | All |
| Enrollment | 30 (estimated) |
| Sponsor | Jules Bordet Institute Academic / other |
| Drugs / interventions | chemotherapy |
| Locations | 2 sites (Brussels, Brussels Capital and 1 other locations) |
| Status | Recruiting |
| Started | March 1, 2026 |
| Main results expected | December 2028 |
| Study ends | December 2028 |
| Registry record updated | October 26, 2026 |
| Trial ID | NCT07474025 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults (≥18) with histologically confirmed colorectal adenocarcinoma and suspected or confirmed peritoneal metastases undergoing staging laparoscopy and CRS ± HIPEC.
✕Probably not a fit
Patients whose peritoneal metastases do not show clear dominant growth patterns or whose samples are unevaluable may not benefit from this approach.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This prospective, single-center observational pilot looks at whether the dominant histopathological growth pattern at the tumor–peritoneum interface can be reliably identified from limited biopsies taken during staging laparoscopy and later confirmed in cytoreductive surgery specimens. Two blinded pathologists independently estimate the proportions of pushing and infiltrating growth patterns, following a prespecified standard. The study does not use growth patterns to guide treatment. Thirty adults with colorectal peritoneal metastases scheduled for both staging laparoscopy and cytoreductive surgery will be enrolled.
Why it matters
Potential benefit: If successful, this approach could help validate noninvasive biopsy-based proxies for tumor behavior in peritoneal metastases.
How similar studies have gone: Preliminary work in histopathological growth patterns in peritoneal cancer has shown variability; this pilot explores reliability on limited biopsy samples.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Age ≥ 18 years * Histologically confirmed colorectal adenocarcinoma * Suspected or confirmed peritoneal metastases from colorectal cancer based on imaging or prior clinical evaluation * Patients undergoing staging laparoscopy and/or cytoreductive surgery (CRS) ± hyperthermic intraperitoneal chemotherapy (HIPEC) as part of standard clinical care * Availability of peritoneal metastasis tissue samples suitable for histopathological analysis * Written informed consent provided for participation in the study Exclusion Criteria: * Age \< 18 years * Peritoneal metastases originating from non-colorectal primary tumors * Absence of available or adequate peritoneal metastasis tissue samples for histological growth pattern analysis * Patients who decline or withdraw informed consent * Patients unable to provide informed consent
Where it's running
-
Institut Jules Bordet
Brussels, Brussels Capital, Belgium Recruiting -
Hub Bordet
Brussels, Belgium Not yet recruiting
Study contacts
- Study coordinator: Gabriel Professor Liberale, MD, pHD
- Email: gabriele.liberale@hubruxelles.be
- Phone: +32 2 541 31 11
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
CBI-1214 T-cell engager for advanced MSS/MSI-L colorectal cancer
This trial will test whether the experimental T-cell engager CBI-1214 is safe, reaches appropriate blood levels, and can shrink tumors in people with advanced or metastatic MSS/MSI-L colorectal cancer who have had prior treatment.
-
Knife-assisted full-thickness resection for rectal lesions in a multicenter setting
A multicenter study tests knife-assisted full-thickness resection (kFTR) to remove rectal lesions in adults and see how well it works and how safe it is.
-
Personalized 3D Bioprinted Colorectal Cancer Microenvironment Model
This study tests patient-derived, 3D-bioprinted cancer models that include tumor, fibroblast, and immune cells to see if they can better predict how colorectal cancer will respond to treatment.
-
Integrated genomic and clinical database for cancer biomarker discovery
Researchers are building a combined genomic and clinical database at Samsung Medical Center to test biomarkers for cancer diagnosis, treatment choice, and predicting how well treatments work.
-
Prehabilitation with Resistance, Aerobic, or Both Before Colorectal Surgery
Four pre-surgery exercise options (resistance, aerobic, both, or none) will be tested to see which best reduces complications after colorectal cancer surgery.
-
Liver transplantation for colorectal cancer with liver metastases
This study follows adults with stage IV colorectal cancer whose disease is limited to the liver and who are getting a liver transplant as part of their cancer care to see how they fare over time.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.